RGEN
RGEN
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
2
$240K
Insider Sales
17
$29.51M
Total Volume
$29.75M
19 transactions
Net Activity
$29.27M
Net selling
Sentiment Rating
Moderate DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 99% of total transaction value.
- •Minor cluster buying: 2 unique insiders purchased shares.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Hunt Anthony
Dir
$21.26M total
Loeillot Olivier
CEO
$7.69M total
Bylund James
COO
$331K total
Madaus Martin D
Dir
$202K total
Garland Jason K
CFO
$186K total
Quick Actions
RGEN has an insider buy conviction of 1%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at RGEN (RGEN) engaged in a total of 19 transactions reported via SEC Form 4 filings. Among these, 2 were open-market purchases and 17 were sales. The total volume of insider trading reached $29.75M.
The net insider activity for RGEN shows a net selling bias of $29.27M. This activity represents a 1% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Hunt Anthony (Dir), who traded 26.8K shares valued at $4.08M on Mar 17, 2025.
Repligen Corporation (RGEN) Stock Price, News, Quote & History
Repligen Corporation (RGEN) stock price, news, quote and history
Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
Repligen Stock Price Forecast. Should You Buy RGEN?
Repligen (RGEN) Stock Looks Fairly Valued As Cash Flow Growth Matters
RGEN Nov 2026 90.000 call (RGEN261120C00090000) interactive stock chart
Related News & Analyst Reports
Read original insights and educational research covering RGEN and the Unknown sector.
Evaluating a16z Web3 Spinoffs: Insider Activity in Tech Convergence Stocks
Andreessen Horowitz has backed dozens of Web3 startups that later went public. This report tracks board-member Form 4 activity at a16z-affiliated tech convergence companies to identify post-IPO insider conviction signals.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Why Directors Buy Stock in Regional Banks vs. Systemic Banks
Regional bank directors show a much higher propensity for open-market stock purchases than their megabank counterparts. This report explores the governance, ownership structure, and information environment reasons for this divergence, and whether the regional director signal holds predictive value.
FAQs About RGEN Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for RGEN.